Conforma Therapeutics Corporation

Kevin Hong

Marcus F Boehm

Srinivas Rao Kasibhatla

Marco Antonio Biamonte

Lin Zhang

Jiandong Shi

Junhua Fan

Jean-Yves Le Brazidec

David Hurst

Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O); and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

Purine analogs having HSP90-inhibiting activity

A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: 

Pyrazolopyrimidines and related analogs as HSP90-inhibitors

2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

2-aminopurine analogs having HSP90-inhibiting activity

The present invention provides compounds represented by Formula I. Ris selected from hydrogen, halogen, lower alkyl, &#x2014;SR, &#x2014;OR, &#x2014;CN, and &#x2014;NHR, Ris halogen, or lower alkyl; Ris &#x2014;NHR; Ris selected from the group consisting of hydrogen, halogen, &#x2014;SR, &#x2014;OR, &#x2014;CN, &#x2014;C(O)R, &#x2014;C(O)OH, &#x2014;NO, &#x2014;NRR, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, and Ris aryl, heteroaryl, alicyclic, or heterocyclic: 

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, diastereomer, pharmaceutically acceptable salt or prodrug thereof, Wherein Ris halogen, &#x2014;OR, &#x2014;SRor lower alkyl; Ris &#x2014;NHR; Ris &#x2014;CHR&#x2014;, &#x2014;C(O)&#x2014;, &#x2014;C(S)&#x2014;, &#x2014;S(O)&#x2014; or &#x2014;S&#x2014;; and Ris aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 3 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, and the heterocyclic group is substituted with 3 to 5 substituents.

Growing community of inventors

San Diego, CA, United States of America

Kevin Hong